Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma

Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established unresectable cHCC-CCA. Here, we present six cases treated atezolizumab plus bevacizumab. We observed three partial responses one stable disease as the best responses; two these were still being bevacizumab at time reporting (at least five months treatment), whereas remaining unable to continue owing adverse events. Atezolizumab may be an effective